2021
25 January, 2021
Ordinary General Meeting
To the shareholders of FluoGuide A/S The board of directors hereby convenes an ordinary general meeting of FluoGuide to be held on...
25 January, 2021
Change in the Board of Directors of FluoGuide
Arne Ferstad, the Chairman of the Board of Directors, has notified FluoGuide that he will not stand for re-election at the upcoming...
20 January, 2021
Financial calendar for 2021
Financial calendar for 2021: Year-end report 2020 (Q4): 26 January 2021
Annual report 2020: 26 January 2021
Annual General Meeting...
13 January, 2021
FluoGuide gets green light to proceed to third dose level with FG001 in the ongoing clinical phase I/II trial in patients with high grade glioma
Evaluation of the results from the second dose level of FG001, including data from three patients, has been finalized and reported...
2020
29 December, 2020
Board member of FluoGuide sells some of his shares to pay capital gain tax on his shareholding
“Due to Danish corporate tax regulations and the success of FluoGuide during 2020, I have to pay capital gain tax in my holding...
17 December, 2020
FluoGuide gets green light to proceed to second dose level with FG001 in the ongoing clinical phase I/II trial in patients with high grade glioma
Evaluation of the results from the first dose level of FG001, including data from three patients, has been finalized and reported to...
26 November, 2020
FluoGuide’s presentation at Økonomisk Ugebrev’s Life Science event is now available
Økonomisk Ugebrev Life Science conveys the potential of Nordic equities in the BioTech and pharmaceutical sectors. The magazine...
Third quarter 2020 (1 July – 30 September): First nine months 2020 (1 January – 30 September): *) Result per share (DKK...
9 November, 2020
First patient enrolled in the phase I/II clinical trial testing FG001 in patients with high grade glioma
FluoGuide’s phase I/II clinical trial, testing FG001 in patients with high grade glioma consists of two phases; (1) a dose escalation...